CharlesWilliamsFlexnerMD

Professor of Medicine, Johns Hopkins University School of Medicine; Director, AIDS Clinical Trials Unit; Deputy Director, Institute for Clinical and Translational Research

Join to view full profile

Dr. Flexner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Flexner's full profile

Already have an account?

Office
600 N Wolfe St
Baltimore, MD 21287
Phone+1 410-955-1725

Education & Training

Johns Hopkins UniversityFellowship, Infectious Disease, 1988 - 1989
National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1985 - 1987
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1982 - 1985
Johns Hopkins University School of MedicineClass of 1982

Certifications & Licensure

CA State Medical License 1983 - Present
MD State Medical License 1985 - 2026
American Board of Internal Medicine Internal Medicine

Clinical Trials

Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals
Completed
Not Applicable
A Phase I Randomized Dose/Formulation Comparison Study of SC-52151
Completed
Phase 1
Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults
Completed
Phase 1
The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir
Completed
Not Applicable
A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation
Completed
Phase 2
Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients Start of enrollment: 2004 May 01
Completed
Phase 2
Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz Start of enrollment: 2014 Oct 01
Terminated
Phase 4
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection Start of enrollment: 2014 May 30
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

42 citations
Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.
Maddalena Cerrone, Omamah Alfarisi, Megan Neary, Mark A. Marzinke, Teresa L. Parsons
The Journal of Antimicrobial Chemotherapy. 2019-06-01
1669 citations
Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
Diana Finzi, Joel N. Blankson, Janet M. Siliciano, Joseph B. Margolick, Karen Chadwick
Nature Medicine. 1999-05-01
45 citations
Interest of youth living with HIV in long-acting antiretrovirals
Ethel D. Weld, Sohel Rana, Ronald H. Dallas, Andres Camacho-Gonzalez, Patrick Ryscavage
Journal of Acquired Immune Deficiency Syndromes. 2019-02-01

Journal Articles

Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-Chloroquine
Charles Flexner, Michael M Lederman, Theresa A Shapiro, Clinical Infectious Diseases

Lectures

Modern HIV Therapy: Progress and Prospects
Virology Education B.V, Baltimore, Maryland - 11/5/2012

Other

Modern HIV Therapy: Progress and Prospects
Charles Flexner, MD, Clinical Pharmacology & Therapeutics
https://www.doximity.com/articles/d00fecdd-81cc-4143-b68b-e4c067729426
UpToDate, Wolters Kluwer Health - 2012-08-16

Press Mentions

Management of Patients with HIV, Limited Treatment OptionsOctober 26th, 2022
New Approaches to HIV Prevention, Management of Patients with HIVOctober 25th, 2022
Forty Years on, Black Americans Disproportionately Hit by HIVMay 6th, 2021
Join now to see all

Grant Support

Johns Hopkins AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2007–2012
ACTG A5128National Center For Research Resources2005–2007
ACTG A5191National Center For Research Resources2004–2007
ACTG A5001National Center For Research Resources2004–2007
ACTG 362National Center For Research Resources2004–2007
ACTG A5223National Center For Research Resources2006
Johns Hopkins Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2001–2006
Oral ClotrimazoleNational Center For Research Resources2004–2005
Interaction Of Amprenavir (Apv), Lopinavir (Lpv/R), And Efavirenz (EFV)National Center For Research Resources2004–2005
ACTG Screening ConsentNational Center For Research Resources2004–2005
ACTG 5077: Virologic StudiesNational Center For Research Resources2004–2005
Antiretroviral Response To Idv/Rtv Containing Regimen In Hiv-Infected SubjectsNational Center For Research Resources2004
ACTG A5043National Center For Research Resources2004
ACTG 384National Center For Research Resources2004
ACTG 372National Center For Research Resources2004
A5058s: Augmentation Of Hiv-Specific Helper And CTL Response Through TherapeuticNational Center For Research Resources2004
Trial Of Hydroxyurea In Combo With Antivirals In HIVNational Center For Research Resources2000–2002
Trial Of Efv/Nfv In Combo With Zdv/3tc/Idv In AIDSNational Center For Research Resources2000–2002
Protease/Nonnucleoside Transcriptase/Nucleoside HIV TherNational Center For Research Resources2000–2002
Pharmacokinetic Action--Protease Inhibitors &AntilipidsNational Center For Research Resources2000–2002
Nelfinavir Induced Diarrhea--Secretory VS NonsecretoryNational Center For Research Resources2000–2002
HIV Protease Inhibitor &Methadone Metabolism In HIVNational Center For Research Resources2000–2002
Fluconazole VS Episodic In HIV+ PTS With CandidiasisNational Center For Research Resources2000–2002
Blood Lymphocytes From Hiv--Coreceptor Virus IsolationNational Center For Research Resources2000–2002
Amprenavir In Combo With Abacavir/Efavirenz/AdefovirNational Center For Research Resources2000–2002
ACTG 892--Antiretroviral Therapy Effects On Lean BodyNational Center For Research Resources2000–2002
ACTG 365--Pharmacokinetics On Indinavir And RifabutinNational Center For Research Resources2000–2002
Safety And Efficacy Of Ritonavir In Combination With Nelfinavir In HIVNational Center For Research Resources1998–2002
Safety And Antiretroviral Activity Of Hydroxurea And DidanosineNational Center For Research Resources1998–2002
ACT 307--Safety/Antiretrovirl Activity Of Hydroxyurea Alone/Combination With DDINational Center For Research Resources1998–2002
ACTG 307 Dosing Study--Safety &Antiretroviral Activity Of HydroxyureaNational Center For Research Resources1999
Preliminary Antiviral Activity Study Of GEM 91 Administered To HIV+ SubjectsNational Center For Research Resources1998–1999
Phase I/II Multiple Dose Study Of GEM 91 Continuous IV Infusion In HIV+ PatientsNational Center For Research Resources1998–1999
Phase I/II Protocol To Evaluate Electroinserted Rbc-Rcd4 In HIV SubjectsNational Center For Research Resources1997–1999
Rifabutin And Ethambutol Effects On Clarithromycin PharmacokineticsNational Center For Research Resources1997
Pharmacokinetics &Preliminary Antiviral Activity Study Of GEM 91National Center For Research Resources1997